Citation
- Authors: Ioannou, M. S., Kulasekaran, G., Fotouhi, M., Morein, J. J., Han, C., Tse, S., Nossova, N., Han, T., Mannard, E., McPherson, P. S.
- Year: 2017
- Journal: EMBO Rep 18 2119-2130
- Applications: in vitro / DNA / jetPRIME
- Cell types:
- Name: HEK-293T
Description: Human embryonic kidney Fibroblast
Known as: HEK293T, 293T - Name: HeLa
Description: Human cervix epitheloid carcinoma cells - Name: MCF 10A
Description: Human breast adenocarcinoma cells
Known as: MCF10A, MCF 10A
- Name: HEK-293T
Abstract
Epidermal growth factor (EGF) activates the EGF receptor (EGFR) and stimulates its internalization and trafficking to lysosomes for degradation. However, a percentage of EGFR undergoes ligand-independent endocytosis and is rapidly recycled back to the plasma membrane. Importantly, alterations in EGFR recycling are a common hallmark of cancer, and yet, our understanding of the machineries controlling the fate of endocytosed EGFR is incomplete. Intersectin-s is a multi-domain adaptor protein that is required for internalization of EGFR Here, we discover that intersectin-s binds DENND2B, a guanine nucleotide exchange factor for the exocytic GTPase Rab13, and this interaction promotes recycling of ligand-free EGFR to the cell surface. Intriguingly, upon EGF treatment, DENND2B is phosphorylated by protein kinase D and dissociates from intersectin-s, allowing for receptor targeting to degradation. Our study thus reveals a novel mechanism controlling the fate of internalized EGFR with important implications for cancer.